MOR103 Presentation - MorphoSys

ePAPER READ

DOWNLOAD ePAPER

morphosys

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

START NOW

DAS28 Response to Treatment

MOR103 vs Placebo at Day 29 and 57

ACR/ARHP 2012 – Washington DC – November 10-14, 2012

Download the Corporate Factsheet (PDF) - MorphoSys

Consolidated Financial Statements (IFRS) 2011 - MorphoSys

Company Presentation - J.P. Morgan Healthcare ... - MorphoSys

Thank you Claudia, also from me, a warm welcome to ... - MorphoSys

MorphoSys Issued US Patent for HuCALÃ‚Â® Antibody Library

MORPHOSYS AG AND BAYER SIGN AGREEMENT TO APPLY ...

Transcript of Speech and Q&A Conference Call Q2 - MorphoSys

Invitation to the Annual General Meeting 2012 - MorphoSys

Antibody Engineering Conference, San Diego - MorphoSys

Study Design Streptococcal Cell Wall Induced Arthritis - MorphoSys

ACR-Subcomponent Analysis ESR [mm/hour] Median Changes from Baseline Median change from baseline treatment period ACR/ARHP 2012 – Washington DC – November 10-14, 2012 Visit (week)

DAS28 Response to Treatment MOR103 vs Placebo at Day 29 and 57 ACR/ARHP 2012 – Washington DC – November 10-14, 2012

Page 1 and 2: Abstract-Number: L11 First in Patie
Page 3 and 4: Disclosures • F. Behrens, M. Oste
Page 5 and 6: Anti-GM-CSF Monoclonal Antibody (MO
Page 7 and 8: Study design 0.3 mg/kg MOR103 (n=25
Page 9 and 10: Baseline Disease Characteristics Ch
Page 11 and 12: Patient Disposition Placebo (n=27)
Page 13 and 14: ACR Response at Week 4 Percentage o
Page 15 and 16: EULAR Response at Week 4 Percentage
Page 17 and 18: Change of Synovitis by MRI Analysis
Page 19 and 20: Acknowledgements Investigators �
Page 21: Geographic Distribution of Patients

MOR103 Presentation - MorphoSys

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?